Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAdvanced Medical Solutions Group Regulatory News (AMS)

Share Price Information for Advanced Medical Solutions Group (AMS)

Share Price is delayed by 15 minutes
Get Live Data
221.00    4.50 (2.08%)
Bid:
220.50
Ask:
221.00
Spread: 0.50 (0.227%)
Market Cap: £480.08m
AMS Live PriceLast checked at - London Stock Exchange

Intraday Advanced Medical Solutions Group Share Chart

Total Voting Rights

31 Mar 2025 18:26

RNS Number : 0176D
Advanced Medical Solutions Grp PLC
31 March 2025
 

 

31 March 2025

Advanced Medical Solutions Group plc

("AMS" or the "Group")

 

Total Voting Rights

 

In accordance with Disclosure and Transparency Rule 5.6.1, the issued share capital of Advanced Medical Solutions Group plc as at 31 March 2025 comprises 217,994,699 ordinary shares of 5p each with voting rights. There are no shares held in treasury.

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

 

- End -

 

For further information, please visit www.admedsol.com or contact:

 

Advanced Medical Solutions Group plc

Tel: +44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations

 

ICR Healthcare

Tel: +44 (0) 20 3709 5700

Mary-Jane Elliott / Lucy Featherstone

AMS@icrhealthcare.com

Investec Bank PLC (NOMAD & Broker)

Tel: +44 (0) 20 7597 5970

Gary Clarence / David Anderson

 

 

 

About Advanced Medical Solutions Group plc - see www.admedsol.com

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8®, LIQUIFIX™, Peters Surgical, Ifabond, Vitalitec and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made seven acquisitions: Sealantis, an Israeli developer of innovative internal sealants, Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business, Connexicon, an Irish tissue adhesives specialist, Syntacoll, a German specialist in collagen-based absorbable surgical implants and Peters Surgical, a global provider of specialty surgical sutures, mechanical haemostasis and internal cyanoacrylate devices.

 

AMS's products, manufactured in the UK, Germany, France, the Netherlands, Thailand, India, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, France, Poland, Benelux, India, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 1,500 employees. For more information, please see www.admedsol.com.

 

-

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVREAXDFDAASEFA
Date   Source Headline
29th Jan 20214:36 pmRNSTotal Voting Rights
22nd Jan 202111:31 amRNSHolding(s) in Company
12th Jan 20217:00 amRNSDirectorate Change
12th Jan 20217:00 amRNSTrading Update
8th Jan 20215:37 pmRNSHolding(s) in Company
31st Dec 202010:00 amRNSTotal Voting Rights
15th Dec 20209:47 amRNSHolding(s) in Company
30th Nov 20201:29 pmRNSTotal Voting Rights
23rd Nov 20207:00 amRNSAMS Acquisition of Raleigh Coatings
20th Nov 20207:00 amRNSCE mark approval for Silicone PHMB Foam Dressing
16th Nov 20201:29 pmRNSHoldings in Company
19th Oct 20203:29 pmRNSHolding(s) in Company
16th Sep 20207:00 amRNSInterim Results
15th Sep 20202:48 pmRNSBlock listing Interim Review
3rd Sep 20207:00 amRNSNotice of Results
14th Aug 202012:02 pmRNSPrice Monitoring Extension
4th Aug 20207:00 amRNSUK and US Patents Granted for LiquiBand® Exceed
31st Jul 20201:29 pmRNSTotal Voting Rights
9th Jul 20207:00 amRNSTrading Update
30th Jun 20205:52 pmRNSTotal Voting Rights
19th Jun 202012:02 pmRNSPrice Monitoring Extension
15th Jun 202012:02 pmRNSPrice Monitoring Extension
10th Jun 202011:30 amRNSResult of Annual General Meeting
10th Jun 20207:00 amRNSAGM Trading and US LiquiBand® Update
29th May 20202:17 pmRNSTotal Voting Rights
18th May 20207:00 amRNSAnnual Report, AGM and Board Change
12th May 20206:16 pmRNSDirector/PDMR Shareholding
11th May 20204:01 pmRNSDirector/PDMR Shareholding
30th Apr 20202:00 pmRNSTotal Voting Rights
17th Apr 20204:30 pmRNSDirector/PDMR Shareholding
14th Apr 20207:00 amRNSPCA Dealing
6th Apr 20209:26 amRNSDirector/PDMR and PCA Shareholding
6th Apr 20207:01 amRNSClinical Development Programme
6th Apr 20207:00 amRNSDirector/PDMR Shareholding
2nd Apr 20207:00 amRNSCOVID-19 Update
30th Mar 20209:06 amRNSHoldings in Company
13th Mar 20205:00 pmRNSHolding(s) in Company
11th Mar 20207:00 amRNSUnaudited Preliminary Results
10th Mar 20207:00 amRNSBlock listing Interim Review
10th Mar 20207:00 amRNSFDA Approval of LiquiBand® Rapid(TM)
11th Feb 202010:03 amRNSHolding(s) in Company
15th Jan 20207:00 amRNSYear End Trading Update
31st Dec 201912:18 pmRNSTotal Voting Rights
2nd Dec 20197:00 amRNSAcquisition of Biomatlante SA
29th Nov 20193:08 pmRNSTotal Voting Rights
29th Nov 20197:00 amRNSThird party sterilisation failure
31st Oct 20193:13 pmRNSTotal Voting Rights
31st Oct 20193:09 pmRNSHolding(s) in Company
16th Sep 201911:15 amRNSHolding(s) in Company
16th Sep 20197:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.